Md. Mim Obaidullah, Md. Rayhan Chowdhury, Shirmin Islam, Ashok Kumar Barman, Israt Ara Hossain, Mohammad Nurul Matin
J Adv Biotechnol Exp Ther. 2021; 4(2): 210-214.
[View Full Article PDF] [View Crossref] [View Full Article HTML] [View Full Article DOI]
The low percentage of high-density lipoprotein-cholesterol (HDL-C) is strongly accompanied with cardiovascular diseases (CVD) where female are at higher risk than male and are the most dangerous reason of a disease called type 2 diabetes mellitus (T2DM). Although the relationship between gender-specific HDL-C / LDL-C level and T2DM is difficult to understand, however, it is suspected to be linked. To determine the HDL-C and LDL-C ratios among males and females with T2DM subjects, a study was conducted in the Department of Biochemistry Laboratory of BUHS general hospital, Mirpur, Dhaka, Bangladesh from July 2018 to November 2018 among 60 T2DM patients consisting of 30 males and 30 females. Study subjects with ages ranging from 35-65 were included in this study. Serum glucose and lipid profile was analyzed by enzymatic colorimetric method. Among the glycemic profile, the fasting serum glucose levels and 2 h after breakfast (ABF) glucose levels in male and female subjects were measured. The total serum cholesterol was significantly higher in the subject of females T2DM patient compared to male T2DM subjects (p=0.043). However, HDL-C and LDL-C did not show any significant difference between male and female T2DM subjects. In conclusion, our results show hypercholesterolemia among female T2DM subjects compared to male counterparts who might have higher risk of cardiovascular diseases.
Cardiovascular diseases, HDL-C, LDL-C, Triglyceride, Type 2 diabetes mellitus.
The prevalence of diabetes mellitus is overgrowing; around 34 million people in US are living with diabetes . The most prevalent form of heart diseases in individuals with diabetes is coronary heart disease . The type 2 diabetes mellitus (T2DM) is a known cause in the progression of cardiovascular diseases (CVDs). It is naturally associated with some atopic disorders, including low triglyceride levels, high LDL-C, hypertriglyceridemia, and low HDL-C [3-5]. Although the risk of CVDs are relatively higher in T2DM male, it is more common in T2DM female when compared with non-diabetes women [6-9]. Several new studies have shown that female with diabetes are more likely to have CVDs than male who might have higher risk of death [10, 8]. However, women with type-2 diabetes have estrogen scarcity compared with non-diabetic women and decline in estrogen level is one of the major causes of CVDs in the female with diabetes. Moreover, other additional factors including higher level of triglyceride cholesterol, obesity, dyslipidemia, decreased level of HDL are also associated with CVDs [11-13]. Several intensive studies have shown the beneficial impact of lowering LDL-C in the prevention of both primary and secondary CVDs with T2DM treatment [14, 9]. Triglycerides levels may undoubtedly play a role, however, it is not only responsible for CVDs in subjects with T2DM . HDL helps prevent cardiovascular disorders, including atherosclerosis and low levels of HDL-C is the most prominent risk factor of CVDs . Besides, low concentrations of HDL may increase the risk of evolving T2DM through insulin resistance and lowering the function of the β cell of the pancreas . Thus, increasing plasma HDL cholesterol to reduce the risk of type 2 diabetes has been suggested as a unique therapeutic option although the levels of HDL cholesterol associated with type 2 diabetes are virtually unknown [18, 19]. Recently, some works are denoting the relationship among the higher level of triglyceride levels, decreased HDL cholesterol levels, a higher proportion of smaller and denser LDL particles, with diabetics . Therefore, it is becoming more important for male and female to explain the risk factors and clinical manifestations individually to develop separate drugs to get better treatment outcome . So, several works are considering in this regards. The purpose of this study is to determine the level of lipidemic status among T2DM subjects and HDL-C and LDL-C levels between male T2DM and female T2DM.
MATERIALS AND METHODS
It was an observational study where a total of 60 T2DM subjects comprising 30 males and 30 females with ages ranging from 35-65 were recruited from outpatient department (OPD) of Bangladesh University of Health Sciences (BUHS) general hospital. The study was conducted in the Department of Biochemistry Laboratory of BUHS general hospital, Mirpur, Dhaka, Bangladesh from July 2018 to November 2018. Our study was approved by the ethical review board of the Institute of Biological Sciences of the University of Rajshahi, Bangladesh under the certificate number of 255(14)/320IAMEBBC/IBSc. Informed written consents were obtained from all patients enrolled in this study.
Laboratory technique for blood examination
Glucose Oxidase (GOD-PAP) method was used to calculate serum glucose level, serum total cholesterol, and serum high density lipoprotein cholesterol (HDL-C) was measured by enzymatic colourimetric (CHOD-PAP) method using commercially available reagents (T-CHO KL for total cholesterol, Sysmex Co., Hyogo, Japan; Pureauto S TG-N and Cholestest N HDL, respectively, for Serum triglyceride and HDL-C, Sekisui Medical Co., Tokyo, Japan). Serum low density lipoprotein cholesterol (LDL-C) was calculated by the Friedwald formula . Briefly, the original plasma samples had been obtained 12 to 14 h after the last meal, mixed with EDTA (1mg/ml), and immediately stored at 4°C until analyzed. Total plasma cholesterol and tri-glycerides were measured, and data on HDL-C, and LDL-C obtained by a combination of ultracentrifugation and precipitation procedures. All tests analysis were done by using a clinical chemistry analyzer (Dimension RxLsiemens, USA).
Statistical analysis was done using MS Excel for graph representation and SPSS 17.0 for the value of mean ± SD. A P value<0.05 was considered as statistically significant.
Glycemic status of the total study subjects
Table 1 showed the glycemic status of the total study subjects of T2DM. Among glycemic profile, mean (±SD) fasting and postprandial serum glucose of the total study subjects were 9.55±3.88 and 13.21±4.91, respectively, indicating in diabetic patients’ postprandial serum glucose level remain higher.
Table 1. Glycemic status of the total study subjects. Results were expressed as mean ± SD; n=60 subjects.
Lipidemic profile of the total study subjects
Table 2 showed the lipidemic status of the total study subjects of T2DM. Among the lipidemic status, mean (±SD) of HDL-C, LDL-C, total cholesterol, triglyceride, and the ratio of HDL- C and LDL-C of the total study subjects were 41.08±11.53, 126.45±38.82, 203.92±45.34, 221.15±203.06, and 0.35±0.14, respectively. Closer scrutiny of these results revealed that most such patients had very high plasma triglyceride concentrations.
Table 2. Lipidemic profile of the total study subjects. Results were expressed as mean ± SD; n = 60 subjects.
Glycemic and lipidemic status among male and female T2DM subjects
Table 3 showed the comparison of glycemic and lipidemic status among male and female T2DM subjects. Among the glycemic profile, the fasting serum glucose levels in male and female subjects were 10.44±3.94 and 6.25±0.53, respectively. Whereas, the 2 h ABF serum glucose levels in male and female subjects were 13.61±5.43 and 11.87±2.20, respectively. The results indicating that the fasting blood glucose in males were substantially higher than in females (p<0.001).
Table 3. Glycemic and lipidemic status among male and female T2DM subjects. Results were expressed as mean ± S.D.; n = 30 subjects
Lipidemic status among male and female T2DM subjects
Table 4 showed the lipidemic status among female and male T2DM subjects. In female T2DM subjects, the high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, total cholesterol, triglyceride, and HDL- C/LDL-C were 40.3±11.70, 128.11±38.03, 209.93±46.13, 238.20±224.34, and 0.33±0.13, respectively. Accordingly, in male counterparts, these values were 43.50±11, 121±42.29, 184.14±37.61, 165.14±92.29, and 0.39±0.14, respectively. Among lipidemic status, serum cholesterol was significantly higher in the subject of T2DM male compared to the T2DM female (p = 0.043). However, the HDL-C and LDL-C does not show any significant difference between male and female T2DM subjects. Therefore, HDL-c and LDL-c level according to different age group would be effective for identifying risk status of CVDs.
Table 4. Lipidemic status among male and female T2DM subjects. Results were expressed as mean ± S.D.; n = 30 subjects
People with diabetes have lately been considered as one of the critical triggers of heart failure, ischemic heart disease and others commonly called cardio vascular diseases. The cardiovascular diseases with higher triglycerides, low HDL cholesterol, and high-density LDL particles have recently been considered as a marker to characterize type 2 diabetes [23-25]. Although type 2 diabetes and CVDs are more common in male than in female, the female often have a higher risk of severe complications and death [26, 27]. The risk of cardiovascular diseases are slightly greater in diabetes patients than in non-diabetic one. Nevertheless, growing evidence suggests that the risk of developing coronary artery diseases (CADs) varies according to gender where female faces worse situation than male [28, 29]. For comparing cardiovascular diseases among people with diabetes in males and females, our recent work can provide valuable clues to researchers and policy makers for its effective management. The outcomes of the work indicated that fasting blood glucose was significantly higher in male compared to the female T2DM subjects, (p<0.001). The HDL-C, LDL-C, total cholesterol, triglyceride, and HDL- C/LDL-C were 40.30±11.70, 128.11±38.03, 209.93±46.13, 238.20±224.34 and 0.33±0.13 in female and 43.50±11, 121±42.29, 184.14±37.61, 165.14±92.29 and 0.39±0.14 in male, respectively. The average HDL- C/LDL-C was non-significantly higher in male T2DM relative to female T2DM.The other researchers are supporting our findings. A narrative study, which involved a mixture of 37 possible trials, found that the relative risk of severe coronary heart diseases were more significant in female than in male with diabetes . LDL management in diabetic patients considering age and gender evaluated that as a high level of LDL is related to CVDs . Although the symptoms of diabetes is more or less similar in males and females, females become more susceptible to CVDs than males. Further findings showed that in the absence of diabetes, young female and middle-aged female appear to develop less CADs than men, however, in the presence of diabetes, there was not significant differences for the incidence of CADs between men and women . Upon consideration of hypertension, BMI, smoking, HDL, and non-HDL cholesterol, and medicine use, the CADs hazard ratio differed significantly in non-diabetic men than that of women, however, differences was less in case of diabetic patients . Therefore, management of triglyceride level is essential in patients with diabetics, especially in female due to having a higher level of LDL, triglycerides, and lower level of HDL. Modern drugs should launch considering risk factors associated with people with diabetes related CVD .
Increased levels of triglycerides and LDL in the female with diabetes and a decrease in HDL levels indicate that females are in more vulnerable conditions due to diabetes. So, the physicians should consider the goal of personalizing their therapeutic activities to be able to influence their gender-specific conditions, especially CVDs risk in T2DM individuals.
The authors wish to thank Department of Biochemistry and Cell Biology, Bangladesh University of Health Sciences (BUHS), Mirpur, Dhaka-1216 and Department of Genetic Engineering and Biotechnology, University of Rajshahi, Rajshahi-6205, Bangladesh, for providing financial support and other facilities during the whole research work. The authors received not specific funding for this research.
MMO, I.A.H., M.N.M.; Conceptualization. MMO, I.A.H., M.N.M.; Methodology. I.A.H., M.N.M.; Investigation. MMO, SI, M.R.C.; Writing-original draft preparation. MMO, M.R.C., SI, M.N.M.; Writing-review and editing. MMO, M.R.C., SI; Manuscript revision. I.A.H., M.N.M.; Supervision. All authors read and approve the final version of the article.
CONFLICTS OF INTEREST
There is no conflict of interest among the authors.
 Centers for Disease Control and Prevention. National diabetes statistics report, 2020. Atlanta, GA: Centers for Disease Control and Prevention, US Department of Health and Human Services. 2020.
 Ahmed HH, Shousha WG, El-mezayen HA, Emara IA, Hassan ME. New Biomarkers as Prognostic Factors for Cardiovascular Complications in Type 2 Diabetic Patients. Indian J Clin Biochem. 2020;35:54–62.
 Dhas Y, Banerjee J, Mishra N. Blood Viscosity, Glycemic Markers and Blood Pressure: A Study in Middle-Aged Normotensive and Hypertensive Type 2 Diabetics. Indian J Clin Biochem. 2020;35:102–8.
 Quispe R, Martin SS, Jones SR. Triglycerides to high-density lipoprotein-cholesterol ratio, glycemic control and cardiovascular risk in obese patients with type 2 diabetes. Curr Opin Endocrinol Diabetes Obes. 2016;23:150–6.
 Surekha Rani H, Madhavi G, Ramachandra Rao V, Sahay BK, Jyothy A. Risk factors for coronary heart disease in type II diabetes mellitus. Indian J Clin Biochem. 2005;20:75–80.
 Akhileshwar V, Patel SP, Katyare SS. Diabetic cardiomyopathy and reactive oxygen species (R.O.S.) related parameters in male and female rats: A comparative study. Indian J Clin Biochem. 2007;22:84–90.
 Kannel WB, McGee DL. Diabetes and glucose tolerance as risk factors for cardiovascular disease: The Framingham study. Diabetes Care. 1979;2:120–6.
 Huxley R, Barzi F, Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: Meta-analysis of 37 prospective cohort studies. Br Med J. 2006;332:73–6.
 Russo G, Pintaudi B, Giorda C, Lucisano G, Nicolucci A, Cristofaro MR, et al. Age- and gender-related differences in LDL-cholesterol management in outpatients with type 2 diabetes mellitus. Int J Endocrinol. 2015;2015. https://doi.org/10.1155/2015/957105
 Rivellese AA, Riccardi G, Vaccaro O. Cardiovascular risk in women with diabetes. Nutr Metab Cardiovasc Dis. 2010;20:474–80.
 Adinortey MB, Gyan BE, Adjimani J, Nyarko P, Sarpong C, Tsikata FY, et al. Dyslipidaemia associated with type 2 diabetics with micro and macrovascular complications among Ghanaians. Indian J Clin Biochem. 2011;26:261–8.
 Almourani R, Chinnakotla B, Patel R, Kurukulasuriya LR, Sowers J. Diabetes and Cardiovascular Disease: an Update. Curr Diab Rep. 2019;19:161 https://doi.org/10.1007/s11892-019-1239-x
 Dantas APV, Fortes ZB, de Carvalho MHC. Vascular disease in diabetic women: Why do they miss the female protection? Exp Diabetes Res. 2012; doi:10.1155/2012/570598.
 Colhoun HM, Betteridge DJ, Durrington PN. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): Multicentre randomized placebo-controlled trial. A.C.C. Curr J Rev. 2004;13:34.
 Ye X, Kong W, Zafar MI, Chen LL. Serum triglycerides as a risk factor for cardiovascular diseases in type 2 diabetes mellitus: A systematic review and meta-analysis of prospective studies. Cardiovasc Diabetol. 2019;18.
 Vergeer M, Holleboom AG, Kastelein J.J.P., Kuivenhoven JA. The HDL hypothesis: Does high-density lipoprotein protect from atherosclerosis? J Lipid Res. 2010;51:2058–73.
 Kostapanos MS. High density lipoproteins and type 2 diabetes: Emerging concepts in their relationship. World J Exp Med. 2014;4:1.
 Giri R, Kesavulu MM, Kameswara Rao B, Ramana V, Appa Rao C. Hyperlipidemia, increased lipid peroxidation and changes in antioxidant enzymes, Na+-K+-atpase in erythrocytes of type 2 diabetic patients in Andhra Pradesh. Indian J Clin Biochem. 1999;14:168–75.
 Haase CL, Tybjerg-Hansen A, Nordestgaard BG, Frikke-Schmidt R. HDL cholesterol and risk of type 2 diabetes: A mendelian randomization study. Diabetes. 2015;64:3328-33.
 Lazarte J, Hegele RA. Dyslipidemia Management in Adults With Diabetes. Can J Diabetes. 2020;44:53-60.
 Mosca L, Benjamin EJ, Berra K, Bezanson JL, Dolor RJ, Lloyd-Jones DM, et al. Effectiveness-based guidelines for the prevention of cardiovascular disease in women-2011 update: a guideline from the American Heart Association. J Am Coll Cardiol. 2011;57:1404-23. doi:10.1016/j.jacc.2011.02.005
 Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;
 Howard BV, Robbins DC, Sievers ML, Lee ET, Rhoades D, Devereux RB, et al. LDL cholesterol as a strong predictor of coronary heart disease in diabetic individuals with insulin resistance and low LDL: The Strong Heart Study. Arterioscler Thromb Vasc Biol. 2000;20:830–5.
 Garg A, Grundy SM. Treatment of dyslipidemia in patients with NIDDM. Diabetes Rev. 1995;3:433-45.
 Weerarathna TP, Herath HMM, Liyanage G. Prevalence of low HDL cholesterol and its associations among Sri Lankan patients with diabetes mellitus on statin therapy. Diabetes Metab Syndr Clin Res Rev. 2017;11:S253–6.
 Siddiqui M, Khan M, Carline T. Gender Differences in Living with Diabetes Mellitus. Mater Socio Medica. 2013;25:140.
 Gao Z, Chen Z, Sun A, Deng X. Gender differences in cardiovascular disease. Med Nov Technol Devices. 2019;4:100025.
 Maas AHEM, Appelman YEA. Gender differences in coronary heart disease. Neth Heart J.2010;18:598–603.
 Madonna R, Balistreri C, De Rosa S, Muscoli S, Selvaggio S, Selvaggio G, et al. Impact of Sex Differences and Diabetes on Coronary Atherosclerosis and Ischemic Heart Disease. J Clin Med. 2019;8:98.
 Kalyani R.R., Kalyani RR, Lazo M, Ouyang P, Turkbey E, Chevalier K, et al. Sex differences in diabetes and risk of incident coronary artery disease in healthy young and middle-aged adults. Diabetes Care. 2014;37:830–8.
 Avogaro A, Giorda C, Maggini M, Mannucci E, Raschetti R, Lombardo F, Spila-Alegiani S, Turco S, Velussi M, Ferrannini E. Incidence of coronary heart disease in type 2 diabetic men and women: impact of microvascular complications, treatment, and geographic location. Diabetes care. 2007;30: 1241-7.
 WHO; World Health Organization. https://www.who.int/data/gho/indicator-metadata-registry/imr-details/2380.